Catalyst Calendar • Endpoint Arena

Catalyst Calendar

Fri, Jul 10, 2026

1 updates

10:27 AM

Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector

sanofi.com

Fri, Jun 12, 2026

1 updates

7:29 PM

Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

sanofi.com

Thu, May 28, 2026

1 updates

1:00 AM

Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease

sanofi.com

Mon, May 18, 2026

1 updates

3:47 PM

ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

Presentation / Abstract • Phase 2ATS presentation Mon, May 18, 2026sanofi.com

Tue, May 5, 2026

1 updates

7:00 AM

DDW: Sanofi and Regeneron’s DUPIXENT® demonstrates improved esophageal function in eosinophilic esophagitis phase 4 study

Presentation / Abstract • Phase 4sanofi.com

Wed, Apr 22, 2026

3 updates

5:30 PM

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

sanofi.com

1:05 AM

Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children

sanofi.com

1:00 AM

Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US

sanofi.com

Sat, Apr 18, 2026

1 updates

6:00 AM

ESCMID: Sanofi’s NUVAXOVID™ COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study

Trial Results • Phase 4sanofi.com